AIC
BPMC

Ameritas Investment Company’s Blueprint Medicines BPMC Stock Holding History

Ameritas Investment Company’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-50
Closed -$4K – 924
2019
Q3 		$4K Buy
+50
New +$4.32K ﹤0.01% 1312

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameritas Investment Company's BPMC Position: Q4 2019 in Review

Ameritas Investment Company sold out of Blueprint Medicines (BPMC) in Q4 2019, closing a stake of 50 shares — an estimated $4K sold.

Ameritas Investment Company first reported a position in BPMC in Q3 2019 and held it in 1 quarter. The position peaked at $4K in Q3 2019. 228 funds tracked by Wall St. Rank hold BPMC as of Q4 2019.

  • Ameritas Investment Company reported no remaining Blueprint Medicines position as of Q4 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 50 Blueprint Medicines shares in Q4 2019, an estimated $4K.
  • Ameritas Investment Company first reported a position in Blueprint Medicines in Q3 2019 and held it in 1 quarter.
  • Ameritas Investment Company's Blueprint Medicines position peaked at $4K in Q3 2019.
  • 228 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2019.

Based on Ameritas Investment Company's 13F filing for Q4 2019, filed 18 Feb 2020.